Efficacy and immunologic responses to neoadjuvant anti-PD-1 in clinical stage IIC melanoma are associated with tumor burden.

Neoadjuvant immune checkpoint therapy has demonstrated improved event-free survival in patients with resectable clinical stage III/IV melanoma, however its benefit in clinical stage IIB/C melanoma is unknown. Here we present clinical and immunologic data from the first multicenter phase II trial of neoadjuvant pembrolizumab (anti-PD-1) in clinical stage IIB/C melanoma. Sixty-three patients (29 clinical stage IIB, 34 clinical stage IIC) were included, with the primary outcome of sentinel lymph node (SLN) positivity rate after single dose neoadjuvant pembrolizumab. In the overall cohort, there was no significant difference in SLN positivity rate compared to the projected historical rate; however, on subgroup analysis, neoadjuvant anti-PD-1 was associated with a reduction of SLN positivity in stage IIC disease that was not seen in IIB. Antigen-specific flow cytometry was performed on blood specimens from 27 trial patients across multiple timepoints. Neoadjuvant PD-1 blockade induced reinvigoration of exhausted CD8 T cells in IIC patients, and not in IIB patients. Employing a combinatorial tetramer system, we detected melanoma-specific CD8 T cells in 71% of IIC patients vs. 23% of IIB patients. Presence of melanoma-specific CD8 T cells was associated with higher recurrence-free survival in IIC patients. Moreover, clinical stage IIC patients had greater tumor burden compared to IIB. These data indicate that clinical activity and tumor-specific immune responses to neoadjuvant anti-PD-1 are preferentially observed in patients that reach a threshold of tumor antigen load that is sufficient for immune activation and identify circulating melanoma-specific CD8 T cells as candidate biomarkers of response. These findings support prospective evaluation of neoadjuvant anti-PD-1 therapy in clinical stage IIC disease in larger randomized studies.

Authors

Institutions

Publication Details

Journal
Research Square
Published
2026-11-20
DOI
https://doi.org/10.21203/rs.3.rs-11706754/v1
Primary Topic
Cancer Immunotherapy and Biomarkers
Type
preprint
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
NOV
preprint

Efficacy and immunologic responses to neoadjuvant anti-PD-1 in clinical stage IIC melanoma are associated with tumor burden.

Sheryl Mitnick, Ravi K. Amaravadi, Tara C. Mitchell, Phyllis A. Gimotty et al.
5 links
Research Square
Cancer Immunotherapy and Biomarkers
preprint

Efficacy and immunologic responses to neoadjuvant anti-PD-1 in clinical stage IIC melanoma are associated with tumor burden.

Sheryl Mitnick, Ravi K. Amaravadi, Tara C. Mitchell, Phyllis A. Gimotty, Rodabe Navroze Amaria, Yichi Zhang, Guanning Wang, Michael A. Davies, Xinze Tan, Jeffrey E. Gershenwald, Alexander Chan Chi Huang, Anushka Dheer, Xiaowei Xu, Giorgos Karakousis, Kelly McMasters, Jason Chesney, Lynn Schuchter, John Miura, Roi Weisner, Anthony Lee, Shira Rosenburg, Mohammad Farooq, Kevin Ma
preprint en

Abstract

Neoadjuvant immune checkpoint therapy has demonstrated improved event-free survival in patients with resectable clinical stage III/IV melanoma, however its benefit in clinical stage IIB/C melanoma is unknown. Here we present clinical and immunologic data from the first multicenter phase II trial of neoadjuvant pembrolizumab (anti-PD-1) in clinical stage IIB/C melanoma. Sixty-three patients (29 clinical stage IIB, 34 clinical stage IIC) were included, with the primary outcome of sentinel lymph node (SLN) positivity rate after single dose neoadjuvant pembrolizumab. In the overall cohort, there was no significant difference in SLN positivity rate compared to the projected historical rate; however, on subgroup analysis, neoadjuvant anti-PD-1 was associated with a reduction of SLN positivity in stage IIC disease that was not seen in IIB. Antigen-specific flow cytometry was performed on blood specimens from 27 trial patients across multiple timepoints. Neoadjuvant PD-1 blockade induced reinvigoration of exhausted CD8 T cells in IIC patients, and not in IIB patients. Employing a combinatorial tetramer system, we detected melanoma-specific CD8 T cells in 71% of IIC patients vs. 23% of IIB patients. Presence of melanoma-specific CD8 T cells was associated with higher recurrence-free survival in IIC patients. Moreover, clinical stage IIC patients had greater tumor burden compared to IIB. These data indicate that clinical activity and tumor-specific immune responses to neoadjuvant anti-PD-1 are preferentially observed in patients that reach a threshold of tumor antigen load that is sufficient for immune activation and identify circulating melanoma-specific CD8 T cells as candidate biomarkers of response. These findings support prospective evaluation of neoadjuvant anti-PD-1 therapy in clinical stage IIC disease in larger randomized studies.

Research Square
The University of Texas MD Anderson Cancer Center (US), University of Louisville (US), Abramson Cancer Center (US), University of Pennsylvania (US)
Good health and well-being
Cancer Immunotherapy and Biomarkers
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Laika access coming soon